Skip to main content

Table 1 Clinical characteristics of the primary-metastatic cohort and pathological information associated with the primary ccRCC tumor

From: BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

  M0 at presentation
(N = 57)
M1
(N = 54)
Total
(N = 111)
Gender
 No 15 (26.3%) 14 (25.9%) 29 (26.1%)
 Yes 42 (73.7%) 40 (74.1%) 82 (73.9%)
Age at Surgery (years)  
 Mean 62.0 58.5 60.3
 Median 63.6 59.1 61.4
 Range (34.9–78.8) (38.2–73.7) (34.9–78.8)
Max Tumor Size (cm)
 Mean 9.6 10.9 10.2
 Median 9.0 10.0 9.5
 Range (2.5–18.0) (2.1–23.0) (2.1–23.0)
2010 pT
 Missing 0 1 1
 1A 3 (5.3%) 1 (1.9%) 4 (3.6%)
 1B 8 (14.0%) 8 (15.1%) 16 (14.5%)
 2A 14 (24.6%) 6 (11.3%) 20 (18.2%)
 2B 4 (7.0%) 5 (9.4%) 9 (8.2%)
 3A 17 (29.8%) 20 (37.7%) 37 (33.6%)
 3B 7 (12.3%) 4 (7.5%) 11 (10.0%)
 3C 2 (3.5%) 1 (1.9%) 3 (2.7%)
 4 2 (3.5%) 8 (15.1%) 10 (9.1%)
2010 pN
 0 18 (31.6%) 20 (37.0%) 38 (34.2%)
 1 4 (7.0%) 9 (16.7%) 13 (11.7%)
 X 35 (61.4%) 25 (46.3%) 60 (54.1%)
TNM Stage
 I 11 (19.3%) 0 (0.0%) 11 (9.9%)
 II 18 (31.6%) 0 (0.0%) 18 (16.2%)
 III 26 (45.6%) 0 (0.0%) 26 (23.4%)
 IV 2 (3.5%) 54 (100.0%) 56 (50.5%)
Grade
 1 1 (1.8%) 1 (1.9%) 2 (1.8%)
 2 14 (24.6%) 5 (9.3%) 19 (17.1%)
 3 32 (56.1%) 31 (57.4%) 63 (56.8%)
 4 10 (17.5%) 17 (31.5%) 27 (24.3%)
BAP1 IHC in Primary Tumor  
 Negative 13 (27.7%) 6 (12.0%) 19 (19.6%)
 Positive 34 (72.3%) 44 (88.0%) 78 (80.4%)
 NAa    14
PBRM1 IHC in Primary Tumor
 Negative 28 (60.9%) 27 (52.9%) 55 (56.7%)
 Positive 18 (39.1%) 24 (47.1%) 42 (43.2%)
 NAa    14
Number of Longitudinal Metastases
 1 34 (59.6%) 41 (75.9%) 75 (67.6%)
 2 15 (26.3%) 12 (22.2%) 27 (24.3%)
 3 6 (10.5%) 1 (1.9%) 7 (6.3%)
 4 2 (3.5%) 0 (0.0%) 2 (1.8%)
  1. aDenotes that the IHC stain was unsuccessful